Reducing AD-Like Pathology in 3xTg-AD Mouse Model by DNA Epitope Vaccine — A Novel Immunotherapeutic Strategy by Movsesyan, Nina et al.
Reducing AD-Like Pathology in 3xTg-AD Mouse Model
by DNA Epitope Vaccine — A Novel Immunotherapeutic
Strategy
Nina Movsesyan
1,2., Anahit Ghochikyan
1., Mikayel Mkrtichyan
1, Irina Petrushina
2, Hayk Davtyan
1,
Purevdorj B. Olkhanud
3, Elizabeth Head
2,4, Arya Biragyn
3, David H. Cribbs
2,4", Michael G.
Agadjanyan
1,2"*
1Department of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, California, United States of America, 2Institute for Brain Aging and
Dementia, University of California Irvine, Irvine, California, United States of America, 3Immunotherapeutics Unit, Laboratory of Immunology, National Institute on Aging,
Baltimore, Maryland, United States of America, 4Department of Neurology, University of California Irvine, Irvine, California, United States of America
Abstract
Background: The development of a safe and effective AD vaccine requires a delicate balance between providing an
adequate anti-Ab antibody response sufficient to provide therapeutic benefit, while eliminating an adverse T cell-mediated
proinflammatory autoimmune response. To achieve this goal we have designed a prototype chemokine-based DNA epitope
vaccine expressing a fusion protein that consists of 3 copies of the self-B cell epitope of Ab42 (Ab1–11) , a non-self T helper
cell epitope (PADRE), and macrophage-derived chemokine (MDC/CCL22) as a molecular adjuvant to promote a strong anti-
inflammatory Th2 phenotype.
Methods and Findings: We generated pMDC-3Ab1–11-PADRE construct and immunized 3xTg-AD mouse model starting at
age of 3–4 months old. We demonstrated that prophylactic immunizations with the DNA epitope vaccine generated a
robust Th2 immune response that induced high titers of anti-Ab antibody, which in turn inhibited accumulation of Ab
pathology in the brains of older mice. Importantly, vaccination reduced glial activation and prevented the development of
behavioral deficits in aged animals without increasing the incidence of microhemorrhages.
Conclusions: Data from this transitional pre-clinical study suggest that our DNA epitope vaccine could be used as a safe and
effective strategy for AD therapy. Future safety and immunology studies in large animals with the goal to achieve effective
humoral immunity without adverse effects should help to translate this study to human clinical trials.
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Introduction
A critical aim in developing therapeutic interventions for
Alzheimer’s Disease (AD) is the identification of suitable targets. It
is estimated that there are currently about 18 million people
worldwide with AD. This number is projected to nearly double by
2025 to 34 million (http://www.who.int). Current data suggest that
the accumulation of neurotoxic amyloid-b-(Ab) may play a central
role in the onset and progression of AD [1]. Accordingly, many
therapies for AD are aimed at reduction of the level of Ab in the
brain and/or blocking assembly of the peptide into pathological
forms that disrupt cognitive function [2]. A potentially powerful
strategy is immunotherapy with anti-Ab antibody that could
facilitate the reduction pathological forms of Ab in the brain. Pre-
clinical and clinical trials have demonstrated that both active [3–6]
and passive [7] vaccination strategies have been effective inmiceand
may be effective in patients with AD [8–10]. However, the first
immunotherapy clinical trial in AD patients was halted when a
subset of individuals immunized with the vaccine containing Ab42
formulated in a Th1-type adjuvant developed adverse events in the
central nervous system [8–15]. While the actual cause of the adverse
events is unknown, speculation has centered on autoreactive cellular
immune responses specific for the T-cell epitope in Ab, or possibly
the adjuvant, and/or the reformulation of the vaccine during the
Phase IIa study [9,10,12,13,16]. In an attempt to avoid the problems
associated with active immunization of elderly AD patients other
strategies have been proposed [17,18]. One of them, passive transfer
of therapeutically potent humanized monoclonal anti-Ab antibody
to AD patients, is currently in clinical trial (AAB-001).
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vaccine composed of the immunodominant self B cell epitope of
Ab42 and a non-self T helper (Th) cell epitope/s. We recently
demonstrated the feasibility of this strategy in wild-type [19] and
APP/Tg mice [20,21]. Data with a peptide epitope vaccine
composed of Ab1–15 or Ab1–11 and a non-self promiscuous T cell
epitope, PADRE [22] suggest that this active immunotherapy
strategy could be effective and safe in humans, because this
vaccine (i) should bind to almost all human HLA-DR molecules
with high affinity; (ii) does not induce autoreactive Th cells while
generating strong non-self Th responses; and (iii) induces
production of high titers of anti-Ab antibody. Interestingly, Elan
and Wyeth used a similar strategy for the development of an AD
protein vaccine (ACC-001), in which an N-terminal sequence of
Ab is conjugated to diphtheria toxin that should provide foreign
Th epitope/s. However, some problems associated with the
development of safe and effective epitope vaccines may still exist.
For example, a peptide epitope vaccine is immunogenic when it is
synthesized on a multiple antigenic peptide (MAP) backbone, but
cannot be easily scaled up for clinical studies. Another issue
associated with a peptide epitope vaccine strategy is the
requirement for a potent conventional adjuvant. The only
adjuvant currently approved for use in humans is Alum, which
may not be capable of inducing strong anti-Ab immunity in elderly
patients as was previously shown in mice [23].
To avoid these problems, we have generated a novel vaccine by
combining our epitope vaccine approach to a DNA vaccine strategy.
Previously, our group [17,24] and later other authors [25–28]
generated a DNA vaccine based on full-length Ab42. Unfortunately,
all of these vaccines induced, at best, only low titers of anti-Ab42
antibody in APP/Tg mice. In addition, this type of vaccine should
not be considered safer than fibrillar Ab42 used in AN-1792 trial,
because it possesses both self-B and self-T cell epitopes within the Ab
peptide. The goal of this study was to develop a fundamentally
different and safer DNA vaccine that could induce strong anti-Ab
antibody without generation of potentially harmful autoreactive T
cells. Accordingly, we prepared a plasmid encoding an immunodo-
minant self-B cell epitope of Ab42, a foreign promiscuous T cell
epitope, PADRE along with a molecular adjuvant, macrophage-
derived chemokine (MDC/CCL22), and tested the efficacy of this
vaccine in a 3xTg-AD mouse model. We hypothesized that this
vaccine should induce strong anti-Ab antibody responses with help
from the MDC-driven anti-inflammatory (Th2-type) CD4
+Th cells
specific to non-self antigen, PADRE.
Results
DNA epitope vaccine induces strong Ab-specific
antibody production using help from PADRE-, but not
Ab-specific Th cells
Previously, we have utilized MDC/CCL22 to induce a Th2-type
immune response to DNA vaccine encoding tumor or viral antigens
and generated high titers of therapeutic antibody [29,30], suggesting
thatthis may alsoenableusto develop a safeand potent AD vaccine.
Totestthishypothesis,wehaveengineereda DNAvaccineconstruct
that encodes MDC fused in frame with three copies of the
immunodominant self-B cell epitope of Ab42 (3Ab1–11), and foreign
Thcellepitope, PADRE[22] (pMDC-3Ab1–11-PADRE,Figure 1A).
TheconstructexpressedandsecretedMDC-3Ab1–11-PADREfusion
protein (,19 kDA), as shown by intracellular staining of pMDC-
3Ab1–11-PADRE transfected CHO cells (Figure 1B) and by
immunoprecipitation of the conditioned media (Figure 1C).
To test the immunogenicity of our DNA epitope vaccine in vivo,
both 3xTg-AD and C57/Bl6 mice of H2
b immune haplotype were
immunized with pMDC-3Ab1–11-PADRE (Figure 1D), and
cellular and humoral immune responses were assessed. Impres-
sively, we detected strong humoral immune responses in both
strains of vaccinated mice (Figures 2A and 3A) as we previously
reported with peptide epitope vaccine formulated in a strong Th1-
type conventional adjuvant [20,21]. In contrast, wild-type and
3xTg-AD mice immunized with control MDC construct fused
with an irrelevant tumor antigen [30] did not produce anti-Ab
antibody (Figure 2A, 3A). Of note, although 3xTg-AD mice
responded to the DNA vaccination by production of high titers of
anti-Ab antibody (456.36157 mg/ml) this response was signifi-
cantly lower than in wild-type mice in accordance with published
results with Ab peptide vaccines [31,32]. Assuming that there is a
possibility of some antibody being already bound up with the Ab
peptide in plasma of 3xTg-AD, but not wild-type mice, thus
lowering the apparent titers, we analyzed anti-Ab antibody
concentrations in immune sera after dissociation of antibody-
antigen complexes as described by [33]. It is appeared that
dissociation of antigen-antibody complexes did not increase the
titers of anti-Aß antibody in sera collected from immune 3xTg-AD
mice (Figures 2A and 3A). In other words, the difference in
concentrations of antibody detected after immunizations of wild-
type and 3xTg-AD mice cannot be explained by binding of
antibody to circulating plasma Ab molecules. It is possible that the
mechanism of B-cell tolerance is involved in lowering titers of anti-
Ab antibody in vaccinated 3xTg-AD mice [34].
Next, we analyzed therapeutic potency of anti-Ab antibody
from immune 3xTg-AD mice in vitro. As we expected from our
previous studies, this antibody bound not only to Ab42 peptide by
ELISA, but also to monomeric, oligomeric, and fibrillar forms of
this human peptide in dot blot assay (data not shown), and Ab
deposits in brain tissue from an AD case (Figure 2B).
As we expected, the DNA epitope vaccine also induced robust
anti-PADRE, but not anti-Ab T cell immunity in 3xTg-AD mouse
model. More specifically, DNA vaccine activated CD4
+T cells
after their in vitro re-stimulation with PADRE (Figure 3B), but not
Ab40 peptide (data not shown). This anti-PADRE cellular immune
response that ultimately provides help to Ab-specific B cells was
Th2-polarized, as was shown by FACS assay used for the detection
of Th1- (IFNc) or Th2- (IL-4) type intracellular cytokines
(Figure 3C). These data on generation of PADRE, but not anti-
Ab specific Th cells were confirmed in two independent
experiments with vaccinations of C57/Bl6 mice (data not shown)
and supported our previous results generated with peptide epitope
vaccine [20,21]. In addition, the subclass of IgG that is induced
after immunization is an indirect measure of the relative
contribution of Th2-type cytokines versus Th1-type cytokines
[35]. As shown in Figure 3D, immunization of 3xTg-AD mice
with the DNA epitope vaccine induced primarily a Th2-biased
humoral immune response. Such IgG1-polarized antibody
responses were also detected in wild-type mice vaccinated with
the DNA epitope vaccine (Figure 2C). The IgG1/IgG2a
b ratios in
the immunized non-transgenic and 3xTg-AD mice were equal to
32.463.2 and 16.762, respectively (Figure 2D). Thus, our
construct with the MDC molecular adjuvant generates a high
concentration of Ab-specific antibody and directs immune
responses in both wild-type and 3xTg-AD mice towards an anti-
inflammatory Th2-phenotype.
DNA epitope vaccine prevents cognitive dysfunction in
immunized animals
To demonstrate that vaccination initiated in young 3xTg-AD
mice without pre-existing AD-like pathology is beneficial as they
age to 1860.5 mo old, we measured spatial learning and memory
DNA Epitope Vaccine for AD
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with irrelevant antigen) and immunized animals using the Morris
Water Maze (MWM) [36]. Additionally, a fourth group consisting
of age-matched non-transgenic mice of the same haplotype was
used as a pathology-free control. As shown in Figure 4A, the
latency to reach the platform for 3xTg-AD immunized mice
Figure 1. Schematic representation of DNA vaccine construct, its expression, and immunizations schedules. A) Fusion gene encoding
epitopevaccine,3Ab1–11andPADRE(aKXVAAWTLKAAaZC,x=L-cyclohexylalanine,Z=aminocaproicacid)wasintroducedintopCMVE-AB/hMDCinframe
to the 39-end of mature MDC exactly as shown. MDC gene is fused to the IP10 signal sequence in its 59-end and to the 3Ab1–11-PADRE minigene in its 39-
end through small spacer. Transcription of MDC-3Ab1–11-PADRE gene is controlled by CMV promoter/enhancer. B) To analyze the intracellular expression
ofpMDC-3Ab1–11-PADRE,transientlytransfectedCHOcellswerepermeabilized/fixedandstainedwithanti-Ab6E10antibodyfollowedbyFITC-conjugated
anti mouse IgG. Cells were analyzed by FACScan. Approximately ,65% of CHO cells transfected with pMDC-3Ab1–11-PADRE showed 6E10-positive
staining. Cells transfected with control vector showed only background staining. C) The secretion of MDC-3Ab1–11-PADRE by transfected CHO cells was
demonstrated by IP/WB. MDC-3Ab1–11-PADRE protein was immunoprecipitated from the growth medium of transfected CHO cells with anti-Ab antibody
(6E10), separated by 15% Tris-SDS PAGE and transferred onto nitrocellulose membrane. Proteins were visualized by staining with 6E10 followed by HRP-
conjugated anti-mouse IgG. Lane 1 represent vector (pCMVE-AB/MDC); Lane 2 represent Epitope Vaccine (pMDC-3Ab1–11-PADRE). D) 3–4 mo old C57/Bl6
(n=6)or 3xTg-AD (n=4)mice wereimmunized 5 times biweekly. Bloodwas collectedafter 3
rd,4
th and 5
thimmunizations and humoral immuneresponse
was analyzed in sera. Seven days after the last immunization mice were sacrificed and cellular immune response was analyzed in splenocytes. Experiment
with C57/Bl6 mice was repeated (total n=12). Next, 3–4 mo old 3xTg-AD (n=9) mice were immunized 11 times as indicated. Blood was collected and
humoral immune response was analyzed in sera. After 11
th immunization behavioral studies were conducted and upon its completion, mice were
sacrificed and neuropathological changes were analyzed in the brains of experimental and control mice.
doi:10.1371/journal.pone.0002124.g001
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PLoS ONE | www.plosone.org 3 May 2008 | Volume 3 | Issue 5 | e2124Figure 2. DNA epitope vaccine induces strong Th2 polarized humoral immune responses specific to human Ab. A) DNA epitope
vaccine induces very strong humoral immune response in 3–4 mo old C57/Bl6 mice (n=6). Group of non-vaccinated (n=6) as well as group of mice
(n=6) injected with plasmid encoding MDC fused with irrelevant antigen did not generate anti-Ab antibody. B) Anti-Ab antibody generated in mice
immunized with DNA epitope vaccine recognizes human Ab deposits when used in immunohistochemical experiments in an AD case, and this
binding is blocked by pre-absorption of sera with both Ab42 or Ab1–11 peptide. C) DNA epitope vaccine induces the production of anti-Ab antibody of
predominantly IgG1 isotype in wild-type (C57/Bl6) animals. D) IgG1/IgG2a
b ratio in wild-type (C57/Bl6) and 3xTg-AD mice was equal to 32.463.2 and
16.762, respectively, which is an indirect measurement of Th2-type immune response induced by DNA epitope vaccine. Of note, all experiments with
C57Bl/6 mice were repeated (n=6) with the similar results.
doi:10.1371/journal.pone.0002124.g002
Figure 3. DNA epitope vaccine induces production of high concentrations of anti-Ab antibody in 3xTg-AD mice and activates
proliferation of Th2-polarized PADRE-specific CD4
+T cells. A) Concentrations of anti-Ab antibody were detected in the sera of individual
animals (n=9 vaccinated mice, n=5 MDC-irrelevant control, n=5 non-vaccinated mice) after each immunization. B–C) Proliferation of CD4
+T cells (B)
and production of cytokines by this T cell subset (C) were detected by flow cytometry in pooled splenocyte cultures (n=4) after 5
th immunization.
Data are presented after subtraction of the percent of proliferating or cytokine-producing CD4
+ T cells in non-re-stimulated immune splenocyte
cultures from the percent of proliferating or cytokine-producing cells detected in the cultures of splenocytes re-stimulated with PADRE. D) Th2-
polarization was confirmed by antibody isotypes analysis: vaccine induced primarily IgG1 type antibody.
doi:10.1371/journal.pone.0002124.g003
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9-10 and 11-12 (P,0.05 and P,0.01, respectively) compared to
the groups of control 3xTg-AD mice. Notably, this latency
decrease was similar to a group of non-transgenic mice of the same
age. Retention (probe trials) for spatial information was assessed
1.5 and 24 hours after the last training trial. In the 1.5-hour probe
trial the number of correct quadrant crosses was significantly
higher (P,0.05) in immunized 3xTg-AD mice compared to the
3xTg-AD controls. In the 24-hour probe trial spatial memory was
also significantly improved in the experimental group (P,0.05)
compared to both control groups and was similar to non-
transgenic mice (Figure 4B). Statistically significant improvements
(P,0.01) were also observed when analyzing the initial latency to
reach the platform for immunized 3xTg-AD mice compared to the
control transgenic mice for both 1.5- and 24-hour probe trials
(Figure 4C). These data illustrate that vaccinated mice retain
spatial information as well as non-transgenic mice, and signifi-
cantly better than non-vaccinated 3xTg-AD mice do, i.e. both
short-term (1.5 hr) and long-term (24 hr) spatial reference memory
were improved in immunized animals. Thus, DNA epitope
vaccine, but not plasmid, encoding MDC fused irrelevant antigen
prevented age-related cognitive decline in 3xTg-AD mice.
DNA epitope vaccine prevents development of AD-like
pathology in immune animals
Vaccination significantly reduced Ab burden (both diffuse and
core plaques) in several areas of the brains of immune mice versus
control animals at age 1860.5 mo (Figure 5A). These data were
confirmed by analysis of Thioflavin S-positive core plaques
measured in the brains of experimental and control mice
(Figure 5B). Collectively, these results suggest that the DNA
epitope vaccine is effective in reducing amyloid burden (diffuse
and core plaques) in the brains of 3xTg-AD mice, which at the
start of immunization did not possess Ab pathology (protective
vaccination). A potential problem of immunotherapy could be the
fact that a reduction of insoluble Ab may lead to increased levels of
Figure 4. DNA epitope vaccine improves acquisition and retention of spatial memory in immune mice. A) The escape latency to reach
the platform was significantly decreased in the groups of non-transgenic (n=6) and 3xTg-AD immune mice (n=9) versus age-matched groups of
MDC-irrelevant control (n=5) and non-vaccinated control 3xTg-AD mice (n=5). Four trials per training day for each mouse were used until the
criterion was reached in average #20 sec; maximal time allowed to find the platform=60 sec. B) The number of correct quadrant crosses was
significantly higher in a group of immune 3xTg-AD mice versus age-matched control groups for both 1.5- and 24-hr (short and long memory,
respectively) probe trials. Of note, we did not find significant differences for the time spent in the quadrant opposite to the quadrant containing the
platform during the training (data not shown) C) In both 1.5- and 24-hr probe trials the initial latency to cross the platform location was significantly
lower in a group of immune mice versus both groups of age-matched controls. *P,0.05; **P,0.01; ***P,0.001 denote significant differences with
respect to both MDC-irrelevant control and non-vaccinated 3xTg-AD mice of the same age. Error bars indicate SD.
doi:10.1371/journal.pone.0002124.g004
DNA Epitope Vaccine for AD
PLoS ONE | www.plosone.org 5 May 2008 | Volume 3 | Issue 5 | e2124soluble forms of this peptide [14], primarily oligomers, the most
toxic form for neurons, and impair cognitive function [2]. As
demonstrated in Figure 5C DNA epitope vaccination induced a
significant reduction (P,0.001) of insoluble Ab42, but not Ab40
peptides in the brains of immunized mice compared to control
animals. Importantly, we observed that vaccination significantly
reduced (P,0.001) the levels of potentially toxic forms of amyloid,
soluble Ab42 and Ab40 peptides in the brains of immunized 3xTg-
AD mice (Figure 5D). We further confirmed these results after
comparing experimental and control brain homogenates by a
combination of immunoprecipitation and Western blotting. Our
data demonstrate that 20.1 monoclonal antibody (MoAb)-reactive
Ab oligomers, primarily 3- and 6-mers (,14 and ,28 kDa) were
significantly reduced in the brains of immunized mice (Figure 6).
Even though Ab deposition may be the primary event in AD
pathogenesis, it is clear that tau pathology also plays an important
role in the progression of this disease [37]. Current data suggest
that Ab pathology emerges prior to tau pathology and may
accelerate neurofibrillary tangle (NFT) formation [38,39]. More
recently, it was shown that early-, but not mid- and late-stage tau
Figure 5. DNA epitope vaccine reduces Ab depositions in the brains of immune 3xTg-AD mice at age 1860.5 mo. A) A significant
reduction in Ab load (6E10-immunoreactive core and diffuse plaques) was detected in the hemibrains of vaccinated mice compared to the control
animals (**P,0.01). Representative images of immunized and control mice hemibrains stained with 6E10 (scale bar 50 mm), Ctx-cortex, S-subiculum,
WM-white matter. B) A significant reduction of ThS-positive core Ab plaques was observed in the hemibrains of vaccinated mice (*P,0.05) compared
to the control animals. Shown are representative images of ThS-stained hemibrains of vaccinated or control mice were (scale bar 300 mm), S-
subiculum. C) As a result of DNA epitope vaccination, significant reduction (***P,0.001) of insoluble Ab42 level in brain homogenates was observed,
although, decrease in level of insoluble Ab40 was not statistically significant. D) Both soluble Ab40 and Ab42 levels in brain homogenates of immunized
mice were significantly reduced (***P,0.001) following epitope vaccine immunization. Bars represent average6SD for n=5 in the group of control
mice, and n=9 in the group of vaccinated 3xTg-AD mice.
doi:10.1371/journal.pone.0002124.g005
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mice following active or passive vaccination [40]. We did not
observe changes in the number of HT-7 positive neurons
indicating that vaccination did not decrease total tau accumulation
(Figure 7A). Likewise, we did not observe a significant reduction in
early-(AT100), mid-(AT8), and late-(PHF-1) levels of hyperpho-
sphorylated tau after DNA vaccination (Figure 8). To confirm this
data, we also used more sensitive quantitative ELISA method and
demonstrated that the levels of soluble tau were unaffected by
DNA vaccination (Figure 7B). Although, concentration of
insoluble tau decreased in brains of vaccinated animals compared
with that of control mice, this change was not significant mainly
due to a large variability of tau pathology in individual animals
(Figure 7C). Thus, we concluded that even though tau burden
decreased in immune 3xTg-AD mice, this change was not
significant.
DNA epitope vaccine decreases inflammation and does
not induce hemorrhages in immune mice
To examine inflammation-related pathology, the same brain
regions of immunized and control 3xTg-AD mice used for Ab
burden studies were evaluated for glial activation, lymphocyte
infiltration and microhemorrhages in blood vessels. A quantitative
image analysis of brain tissues stained with anti-GFAP and anti-
CD45 antibodies indicated that reduction of amyloid plaques in
the brains of immune 3xTg-AD mice led to less astrocytosis
(P,0.05) and microglial activation (P,0.001), respectively
(Figure 9A, B).
Previously, it was reported that passive transfer of anti-Ab
antibody [41] or active immunizations with Ab42 formulated in
strong adjuvants, CFA/IFA [42] may induce cerebral micro-
hemorrhages in ,20 months old APP/Tg mice. However,
microhemorrhages have not been reported in aged 3xTg-AD
mice. Characteristic blue hemosiderin-positive profiles were
observed primarily in the neocortical, leptomeningeal, hippocam-
pal and thalamic areas of the brain at a rate of 4.0861.59 and
362.04 per hemibrain in control non-immunized and vaccinated
mice, respectively (Figure 9C). Thus, the DNA epitope vaccine
does not increase the incidence of cerebral microhemorrhages,
suggesting its safe and unique nature. In support and in
accordance with our previous data [21,24], no T cells (CD3
+,
CD4
+, or CD8
+ positive) were detected in the brains of immunized
or control 3xTg-AD mice (data not shown).
Discussion
Current interest in immunotherapy for AD is based on the
amyloid cascade hypothesis [1] and the fact that Ab specific
antibody can inhibit accumulation and facilitate the clearance of
Ab deposits from the brains of various AD mouse models [3–5,7]
and AD patients [8–15]. Although the first clinical trial with the
AN-1792 vaccine was halted because of unexpected cerebral
inflammation detected in a subset of participants, presumably due
to infiltration of autoreactive T cells rather than anti-Ab antibody,
caused the significant adverse effects in the vaccinated patients
[9,10,12]. In fact, the presence of high titers of anti-Ab antibody in
the sera of vaccinated mice [21,43] correlates with the reduction of
Ab pathology and was linked to improved spatial learning for
vaccinated PDAPP mice [43]. High titers of antibody may also be
therapeutically beneficial in AD patients [13,14]. Herein, we
report that our DNA epitope vaccine induces very robust anti-Ab
humoral and Th2-polarized immune responses, and prevents the
development of cognitive deficits in aged 3xTg-AD mice.
Importantly, the DNA epitope vaccine does not generate
autoimmune cellular responses specific to Ab similar to that
reported with a peptide epitope vaccine [20,21]. Therefore, this
DNA epitope vaccine may represent a more effective and safer
form of active immunotherapy in humans given the induced Th2-
type of immune response, less activated microglia and astrocytosis
due to the reduction of Ab plaques, and the lack of immunother-
apy-induced microhemorrhages in vaccinated 3xTg-AD mice.
The attractive feature of a vaccine including MDC/CCL22 as
the molecular adjuvant is that it is controlled by the expression of
Th2-type chemokine that plays a critical role in the antigen-
induced recruitment of Th2 cells via chemotaxis, activation of
CCR4-expressing Th2-type CD4
+T cells [44–46] followed by B-
cell activation [29]. These features of MDC have been associated
with its superb efficiency to induce humoral and Th2 responses
without detectable CD8
+ T cell responses when used as fusions
with weakly immunogenic antigens [29]. Typically, approaches
Figure 6. The level of oligomeric forms of Ab detected in hemibrain homogenates by combination of IP with WB using biotinylated
anti-Ab 20.1 monoclonal antibody. Densitometric quantification of bands (relative optical density) revealed significant reduction in the level of
Ab oligomers (3-mers and 6-mers) in brain extracts from immune mice in comparison to control animals (*P,0.05 and ***P,0.001, respectively). Of
note, in these experiments we did not detect clear bands of higher molecular weight oligomers in the soluble extracts of proteins from brains of
vaccinated or non-vaccinated 3xTg-AD mice. Representative picture of WB is presented (Lanes 1-3 non-vaccinated, lanes 4-6 vaccinated).
doi:10.1371/journal.pone.0002124.g006
DNA Epitope Vaccine for AD
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of immunohistochemical staining showing no differences in the levels of total tau (HT-7) in the hemibrains of vaccinated and control mice (scale bar
50 mm), Hp-hippocampus. B–C) Quantitative analysis (ELISA) of SDS-extracted (soluble) tau level revealed no differences between vaccinated and
control mice (B). Decrease in the levels of FA-extracted (insoluble) tau was not statistically significant (C).
doi:10.1371/journal.pone.0002124.g007
Figure 8. Decrease in the levels of phosphorylated tau detected in the brains of vaccinated mice was not statistically significant. A)
Image analysis of immunohistochemical staining demonstrates no differences in the levels of early-stage phosphorylated tau (AT100) in the
hemibrains of vaccinated and control mice. Representative images of hippocampal regions (Hp) from vaccinated and non-vaccinated mice are
presented (scale bar 100 mm). B) Image analysis of immunohistochemical staining demonstrates no differences in the levels of mid-stage
phosphorylated tau (AT8) in the hemibrains of vaccinated and control mice Representative images of hippocampal regions (Hp) from vaccinated and
non-vaccinated mice are presented (scale bar 100 mm). C) Image analysis of immunohistochemical staining demonstrates no differences in the levels
of late-stage phosphorylated tau (PHF) in the hemibrains of vaccinated and control mice Representative images of hippocampal regions (Hp) from
vaccinated and non-vaccinated mice are presented (scale bar 100 mm).
doi:10.1371/journal.pone.0002124.g008
DNA Epitope Vaccine for AD
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increase the efficiency of antigen presentation between 100- to
10,000-fold [47]. In accordance with our previous reports on the
mechanism of chemokine-based vaccines [48,49], we believe that
our DNA epitope vaccine was efficiently delivered and internal-
ized into endo/lyzosomal compartments of target CCR4
+
Antigen-Presenting Cells (APCs). As a result, Ab and PADRE
were also processed and presented onto MHC class II molecules to
maintain a needed Th help for generation of anti-Ab antibody. In
fact, only few micrograms of DNA epitope vaccine were sufficient
for induction of strong anti-PADRE Th2-polarized responses and
high levels of anti-Ab antibody in wild-type and 3xTg-AD mice
(Figures 2 and 3). One may suggest that molecular adjuvant
incorporated into our DNA epitope vaccine could lead to the
production of Th2 cytokines that, in turn, may cross the Blood
Brain Barrier and contribute to Ab clearance in the brains of
vaccinated 3xTg-AD mice. However, the measurement of Th1
and Th2 cytokines in the brain extracts of experimental and
control animals (non-vaccinated and injected with MDC-irrele-
vant antigen) demonstrated that this is not the case. In fact,
immunizations with plasmids, encoding either AD epitope vaccine
or irrelevant antigen, did not alter concentrations of cytokines in
the brains of mice (data not shown).
The beneficial effects of anti-Ab antibody in reducing the
soluble Ab forms have been emphasized, because Ab oligomers
appear to play a critical role in the pathogenesis of AD [2]. Our
DNA vaccine generated high titers of antibody specific to Ab
inhibiting the accumulation of soluble/oligomeric forms of Ab
peptide (Figure 5) and significantly reduced development of age-
related behavioral impairment in 3xTg-AD mice (Figure 4).
Another important issue is the association of tau pathology with
Ab accumulation. Data from AD patients and mouse models of
AD suggested that Ab pathology emerges prior to tau pathology
and accumulation of Ab results in increased NFT formation
[38,39]. Previously, it was shown that the number of AT100, but
not AT8- and PHF-1-positive neurons and NFT was reduced in
,24 mo old 3xTg-AD mice following active or passive vaccina-
tion [40]. In our experiments, the DNA epitope vaccine did not
significantly reduce the number of total tau-positive neurons
(Figure 7). We did not observe significant changes in early-, mid-,
and late-stages of hyperphosphorylated tau (Figure 8), as well as
the levels of soluble and insoluble tau in immune mice (Figure 7).
These differences between our data and [40] may be accounted
for tau pathology not fully developed in our colony of 1860.5 mo
old 3xTg-AD mice and the difference between immunized and
control animals may be detectable at later ages.
In recent years, DNA vaccine technology has received
considerable scientific interest because of significant advantages
of DNA immunization in comparison to other means, i.e. ease of
vaccine development, high stability of the preparation, capability
of modifying genes encoding desired antigen/s, ability to target
cellular localization of an antigen by means of adding or removing
signal sequences or transmembrane domains, and the ability to
selectively elicit the desired type of immune response (humoral or
cellular and proinflammatory or anti-inflammatory [50].
Using this strategy, we reported for the first time on the efficacy of
DNA vaccine based on Ab42 [24]. Later, several other groups
confirmed these data and tested similar types of DNA vaccine in
wild-type and APP/Tg mice [25–28,51]. However, in all these
studies [25–28,51] and in our previous experiments [17] only low
titers of anti-Ab antibody were generated in vaccinated APP/Tg
mice. It is undesirable, because it is known that DNA vaccines are
even lesseffective inlarge animals and humans [50].A DNAvaccine
based ona full-lengthAb42 would not,intheory, be animprovement
to the AN-1792 peptide vaccine because it contains the self-Th cell
epitopes [52,53]. Of note, the recent claim of Ocura and colleagues
[51] that Ab42-based DNA vaccine induced low titer of antibody
without generation of autoreactive Th responses is unsubstantiated,
because Ab42 peptide is the T cell-dependent antigen and requires
helpfromCD4
+T cells(datanot shown).Insharp contrastwith these
studies, our DNA epitope vaccine did not have Ab Th-cell epitope
and, therefore, could not generate autoreactive Th cells, while
inducing strong non-self responses to foreign T cell epitope that was
incorporated in this immunogen.
Figure 9. Vaccination with DNA epitope vaccine leads to less astrocytosis and microglia activation without inducing cerebral
hemorrhages. A) Image analysis of hemibrains stained with anti-GFAP antibody showed significantly less astrocytosis (P,0.05) in mice vaccinated
with DNA epitope vaccine in comparison with control mice (scale bar 50 mm). Representative images of cortical regions (Ctx) from vaccinated and
non-vaccinated mice are presented. B) Image analysis of hemibrains from immunized or control mice, stained with anti-CD45 antibody, showed
significantly less microglia activation (P,0.001) in mice immunized with DNA epitope vaccine. Representative images of hippocampal regions (Hp)
are presented (scale bar 50 mm). C) Level of microhemorrhages in the hemibrains of vaccinated mice did not differ from that in control animals. Image
analysis of hemibrains from vaccinated or control mice were performed after Prussian blue staining. Of note, characteristic blue hemosiderin-positive
profiles were observed in the neocortical, leptomeningeal, hippocampal and thalamic areas of hemibrain. Representative images of cortical (Ctx) and
hippocampal (Hp) regions are presented (scale bar 200 mm).
doi:10.1371/journal.pone.0002124.g009
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based AD vaccine strategy that uses the self-B cell epitope from
Ab, a non-self promiscuous T cell epitope, and a strong molecular
adjuvant, MDC. This DNA epitope vaccine is likely to be effective
and safe in humans, because it (i) should induce strong antibody
responses to Ab without generation of autoreactive Th cells, (ii)
uses PADRE, a promiscuous synthetic Th epitope that is known to
be very effective in the general human population; (iii) uses human
MDC that will activate anti-inflammatory Th2-type cells specific
to the foreign antigen that is not expressed in human brain. In
addition, our preclinical data demonstrate that the DNA epitope
vaccine can also significantly decrease microglial activation and
astrocytosis without increasing the incidence of microhemor-
rhages. Future safety and immunology studies in large animals
with the goal toward achieving effective humoral immunity and
the lowest rate of adverse events should help to translate our DNA
epitope vaccine to human clinical trials.
Methods
Mice
All animal research protocols were approved by the UCI
Institutional Animal Care and Use Committee. 3xTg-AD mouse
model develops two age-related neuropathological features associ-
ated with AD, amyloid plaques and neurofibrillary tangle formation,
as well as age-related behavioral deficits that correlate with the
neuropathology. Three to four month old 3xTg-AD homozygous
mice (provided by the UCI-Alzheimer’s disease research center
(NIH/NIA P50 AG16573) and C57/Bl6 (Jackson Lab, MN) were
housed in a temperature- and light-cycle controlled animal facility at
the Institute for Brain Aging and Dementia (IBAD), University of
California Irvine (UCI). Animal use protocols were approved by the
Institutional Animal Care and Use Committee of UCI and were in
accordance with guidelines of the National Institutes of Health.
DNA Constructs
3Ab1–11-PADRE minigene was generated using overlapping PCR
technique. Each copy of Ab1–11 was separated from the other by GS
small linker. As a mammalian expression plasmid we used pCMVE-
AB/MDC expressing MDC fused in frame with IP10 signal
sequence [29]. 3Ab1–11-PADRE minigene was cloned into
pCMVE-AB/MDC in frame to the 39-end of MDC gene using
XhoI/BamHI restriction sites. pCMVE-AB vector contains CMV
promoter/enhancer and an ampicillin-resistance gene. 3Ab1–11-
PADRE and MDC genes were fused through spacer sequence Asn-
Asp-Ala-Gln-Ala-Pro-Lys-Ser.Thecorrectsequenceofthegenerated
plasmid was confirmed by nucleotide sequence analysis. Plasmids
were purified using Endofree plasmid purification kit (Qiagen, CA) as
recommended by manufacturer. The expression of the plasmid was
detected in transfected CHO cells by immunoprecipitation/western
blot or flow cytometry as previously described [24]. Both IP and WB
were performed with anti-Ab 6E10 monoclonal antibody (Signet,
MA). In addition, WB with anti-human CCL22/MDC antibody
(R&D systems, MN) was also performed. Proteins were visualized
with enhanced chemiluminescence detection using Luminol reagent
(Santa Cruz Biotechnology, CA). Expression of pMDC-3Ab1–11-
PADRE in transfected CHO cells was analyzed using Flow
cytometry assay. Briefly, the transfected CHO cells were fixed and
permeabilized by incubation (20 min at 4uC) with Perm/Fix Buffer
(BD Pharmingen, CA). After washing, cells were stained with
primary 6E10 anti-Ab antibody (Signet, MA) for 30 min at 4uC, and
then with FITC-conjugated rat anti-mouse secondary antibody (BD
Pharmingen, CA) 30 min at 4uC. Samples were analyzed using
FACScan and CellQuest software (BD Biosciences, CA).
Immunization
Three groups of 3xTg-AD mice were included in these studies:
pMDC-3Ab1–11-PADRE (n=13), pMDC-irrelevant control
(n=5) and a group of untreated animals (n=5). The experimental
plasmid was administered by gene gun bombardment (Bio-Rad,
CA) as recommended by manufacturer and previously described
[24]. Each bullet carried 0.5 mg gold (Bio-Rad, CA) coated with
3 mg DNA. Each mouse received 3 shots (total 9 mg DNA) on
shaved abdominal skin using the gene gun with a helium gas of
400 psi. Three vaccinations were performed with a 2-week
interval and continued with one and half monthly immunizations
(total 11). Four mice from the vaccinated group were sacrificed on
7
th day after the fifth immunization, and cellular immune
responses were analyzed.
Detection of anti-Ab antibody in serum and their
functionality testing
On day 7 after each immunization blood was collected for
analysis of anti-Ab antibody by ELISA as we described earlier
[20,21,23,24]. The reaction was developed by adding 3,39,5,59tet-
ramethylbenzidine (TMB) (Pierce, IL) substrate solution and
stopped with 2M H2SO4. The optical density (OD) was read at
450 nm (Biotek, Synergy HT, VT), and antibody concentrations
were calculated using a calibration curve generated with 6E10
monoclonal antibody (Signet, MA). HRP-conjugated anti-IgG1,
IgG2a
b, IgG2b and IgM (Zymed, CA) antibody were used for
characterization of isotype profiles. Dissociation of anti-Ab
antibody from Ab in sera was performed at pH 3.5 as described
earlier [33]. Sera from immunized mice were also screened for the
ability to bind to Ab plaques in the human brain as we previously
described, using immunohistochemistry [24]. A digital camera
(Olympus, Japan) was used to capture images of the plaques at
206 magnification. The binding of antisera (dilution 1:1,000) to
the b-amyloid plaques was blocked by preabsorption of the sera
with 5 mMo fA b1–11 and Ab42 peptides (1 hr, 37uC).
T cell proliferation
To detect T cell proliferation we used sucinimidyl ester of
carboxyfluorescein diacetate (CFSE) assay as we described previ-
ously [21]. Briefly, to detect antigen-specific proliferation of CD4
+
cells, we stained splenocytes cultures with 1 mM CFSE (Molecular
Probes, OR) for 10 min at 37uC.After washing, cells were incubated
3 days in AIM-V media alone or with 2.5 mM of PADRE peptide.
After incubation, cultures were stained with PE-labeled rat anti-
mouse CD4 monoclonal antibody (BD Pharmingen, CA). Since
dead cells might fluoresce non-specifically, these cells were excluded
from the assay using a nucleic acid dye (7-amino actinomycin D, 7-
AAD from BD Pharmingen, CA), and proliferation of viable cells
was analyzed by FACScan flow cytometer (BD Biosciences, CA) as
described by manufacturer. CD4
+ T cells population was analyzed
using CellQuest software (BD Biosciences, CA).
Production of cytokines induced by DNA vaccination
Since IL-4 is a critical cytokine associated with Th2 response,
while INF-c is a marker of Th1 response, it is important to analyze
the presence of these cytokines. FACS was used to detect the
intracellular cytokines by subsets of T cells as previously described
[21]. Briefly, cultures of splenocytes from experimental and
control animals were restimulated for 3–4 days with PADRE
peptide (2.5 mM) and then for 4–6 hr with PMA and ionophore
(ionomycin) (both Sigma, MO). In addition, we added brefeldin A
(BD Biosciences, CA) to block cytokine secretion, which increases
intracellular accumulation. Surface staining was performed using
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CA). Cells were permeabilized, and production of IL-4 or IFN-c
by CD4
+ and CD8
+ T cell subsets was detected using the
appropriate PE-labeled anti-mouse antibody (BD Pharmingen,
CA). The percentages of CD4
+ INF-c
+, CD4
+IL-4
+, and
CD8
+IFN-c
+ cells were calculated in populations of CD4
+ or
CD8
+ T cell subsets using CellQuest software (BD Biosciences).
Detection of different cytokines concentrations in brain
extracts
Five different cytokines (IL-2, IL-4, IL-5, IFN-c and TNF) were
simultaneously detected in brain extracts of experimental and
control mice by Flow cytometry using Mouse Th1/Th2 Cytokine
CBA kit as recommended by manufacturer (BD Biosciences, CA).
Behavior testing: Morris Water Maze
Behavioral testing in 3xTg-AD and wild-type (C57/Bl6) mice
was performed as described in [36]. Briefly, 1860.5 mo old mice,
that had received 11 vaccinations, were trained to swim in a
Morris Water Maze (MWM), an aluminum tank of 1.5 m
diameter with white painted walls and filled with opaque water
maintained at 25–29uC. MWM was located in a room with visual
cues. Prior to training, mice were placed on hidden platform for
10 s to reduce stress. Mice were trained to swim to clear Plexiglas
platform submerged 1.5 cm beneath the surface of the water and
invisible to the mice while swimming. For each mouse, the location
of a platform was chosen randomly but was kept constant through
the training. On each trial the mouse was released into the tank at
one of four designated start locations and allowed to find and
escape onto the platform. If a mouse failed to find the platform
within 60 s, it was manually guided to the platform and allowed to
remain there for 5 s. After this, each mouse was placed into a
holding cage under a warming lamp for 25 s until the start of the
next trial. During the learning period each animal was subjected to
a daily four-trial session for 12 consecutive days until mouse has
reached the criterion (,20 s escape latency). Retention of a spatial
training was assessed 1.5 and 24 hrs after the last training trial.
Both probe trials consisted of 60 s free swimming in the pool with
the platform removed. Mice were monitored with the camera
mounted on the ceiling directly over the pool and recorded on
video tape for subsequent analysis. The parameters measured
during the probe trial were (1) escape latency to cross the platform
location, (2) number of platform location crosses, and (3) time
spent in the quadrant opposite to the one containing the platform
during training.
Brain collection
Immediately after the final behavioral test, both vaccinated and
non-vaccinated mice were sacrificed for further neuropathological
analysis. Mice were anesthetized with Nembutal (40 mg/kg) and
transcardially perfused with ice-cold PBS. Each mouse’s skullcap
was surgically removed; brain was quickly excised and split into
halves by a single mid-saggital cut. The left hemisphere was snap
frozen and reserved for measurement of both soluble/insoluble
Ab40 and Ab42 levels by ELISA as well as tau quantification by
ELISA. The right hemisphere was fixed in 4% paraformaladehyde
in PBS at +4uC for 36 hrs for further sectioning.
Determination of Ab and tau levels in soluble/insoluble
fractions
To determine the levels of both soluble/insoluble Ab40 and
Ab42, frozen left hemispheres of all animals were homogenized
(150 mg/mL) in tissue homogenization buffer (2% SDS in TBS)
with protease inhibitors (Sigma, MO) and phosphatase inhibitors
(Calbiochem, CA). Each sample was briefly sonicated to sheer the
DNA, then centrifuged at 100,0006g for one hour at +4uC.
Supernatant from each sample was drawn off and stored at 280uC
for later quantification of soluble Ab and tau levels. The remaining
pellet was solubilized in 70% formic acid (FA) by sonication and
centrifuged at 100,0006g for 1 hr at +4uC. Avoiding upper lipid
layer, the lower aqueous layer was collected and store at 270uC
for later quantification of insoluble Ab and tau levels. Biosource
ELISA kits (Invitrogen, CA) were used for detection of both Ab40
and Ab42 as well as total tau levels in the brain extracts. Protein
concentration was determined using BCA Protein Assay Kit
(Pierce, IL) and samples were adjusted to the equal concentration.
Western Blot with soluble fractions of brain homogenates from
immune, control and wild-type mice was performed to detect the
level of Ab oligomers as described in[21]. Briefly, proteins were
immunoprecipitated from the brain homogenates of individual
mice with anti-Ab 20.1 monoclonal antibody (Signet, MA),
subjected to electrophoresis on to 4-12% Bis-Tris polyacrylamide
gel in MES buffer under reducing conditions (Invitrogen, CA) and
electrotransferred onto nitrocellulose membrane (GE Healthcare,
NJ). The membrane was blocked with 5% fat-free dry milk
following by detection of Ab oligomers using biotinylated 20.1
monoclonal antibody and HRP-streptavidine. Proteins were
visualized with enhanced chemiluminescence detection using
Luminol reagent (Santa Cruz Biotechnology, CA). Western blots
were scanned and converted into digital files to calculate the
optical density of Ab oligomer spots with NIH Image J software,
version 1.36b. The relative optical density is presented as average
value6SD for each group.
Immunohistochemistry
Free-floating 50 mm-thick coronal sections of fixed hemibrains
were cut using a vibratome, and 6 equally spaced sections from
each brain were used in each staining experiment. Ab deposits
were detected with 6E10 (1:1,000, Signet, MA), activated
microglia and astrocytes were stained with the anti-CD45
(1:300, Serotec, NC) and anti-GFAP (glial fibriliary acidic protein,
1:2,000, Dako, Denmark) antibody, respectively as we described
[21]. To detect the general tau pathology, we used HT7,
recognizing epitopes 159–163 (1:500, Pierce, IL). Phosphorylated
tau was detected with AT100 (p-T212, S214, 1:500, Pierce, IL),
AT8 (p-S202, T205, 1:50, Pierce, IL), and PHF-1 (p-S396, S404;
1:1,000). As a pre-treatment for anti-Ab immunostaining, we used
90% formic acid for 4 min, and for anti-CD45, 0.03 mg/ml
proteinase K for 5 min at RT. All sections were hydrogen
peroxide quenched, blocked and incubated with primary antibody
overnight at +4uC. Incubations with appropriate biotinylated
secondary antibody and ABC for 1 hr were performed followed by
color development using DAB (3,39-diaminobenzidine) substrate
kit (both from Vector Labs, CA). Sections were mounted on
Vectabond coated slides (Vector Labs, CA), dehydrated and
covered using Depex. Thioflavin S was used to visualize fibrillar
Ab. Briefly, mouse brain sections were washed with Tris buffer
and stained for 10 min with a solution of 0.5% Thioflavin S in
50% ethanol, followed by 50% ethanol and Tris buffer, then dried
and covered using Vectashield (Vector Labs, CA). Prussian blue
staining of ferric acid was performed according to the standard
protocol. Sections of mouse brains were stained with Prussian blue
solution made of equal parts of 5% potassium ferrocianide and 5%
hydrochloric acid, for 30 min at RT. After 30 min, sections were
washed in deionized water and counterstained with nuclear fast
red.
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NIH imaging was used to analyze the area occupied by b-
amyloid, glial and Tau reactivity as described previously [21].
Immunostaining was captured using a Sony high-resolution CCD
video camera (XC-77) and NIH image 1.59b5 software. For every
animal, six images from the superficial layer and six images from
the deep layer (5256410 mm each) of the frontal parietal region in
the cortex were captured with a 206objective. For hippocampal
areas, similar imaging was performed for CA1, subiculum and
dentate gyrus. The threshold for the detection of immunoreactivity
was established and then held constant throughout the image
analysis. Thioflavin S-positive plaques and Prussian blue-positive
profiles were counted by visual inspection of cortical and
hippocampal regions of all stained sections while blind to
treatment condition, and the average number of Thio-S and
hemosiderin deposits, respectively, was calculated per each brain
hemisphere by 2 independent observers.
Statistical Analysis
All statistical parameters (mean, standard deviation (SD),
significant difference, etc.) used in immunology, neuropathology
and behavioral studies were calculated using Prism 3.03 software
(GraphPad Software, Inc., CA). Statistically significant differences
were examined using a t-test, or analysis of variance (ANOVA)
and Tukey’s multiple comparisons post-test (P value less than 0.05
was considered significantly different).
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